Puma Bio FDA Advisory Panel Live Blog

Welcome to TheStreet's live blog of the FDA advisory panel reviewing Puma Biotechnology's (PBYI) breast cancer drug neratinib.

This live blog will follow all the action as a group of independent experts hears presentations from the FDA and Puma on the efficacy and safety of neratinib. The panel will then debate the benefits and risks of the drug before taking a vote on whether or not to recommend approval. 

Puma is seeking FDA approval for neratinib as an extended adjuvant breast cancer therapy. That means treating post-surgery breast cancer patients first with one year Herceptin/chemo (standard adjuvant therapy) and then switching them to one year of neratinib.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Stocks

Stocks Fall Ahead of Fed Chair's First Congressional Testimony

Stocks Fall Ahead of Fed Chair's First Congressional Testimony

Goldman Sachs' Quarter Was Too Darn Strong Not to Send Stock Exploding

Goldman Sachs' Quarter Was Too Darn Strong Not to Send Stock Exploding

Video: What Goldman Sachs's CEO Change Means for Banking Stocks

Video: What Goldman Sachs's CEO Change Means for Banking Stocks

Did Netflix Earnings Just Stomp Out Any Chance of a Big Market Rally?

Did Netflix Earnings Just Stomp Out Any Chance of a Big Market Rally?

How to Play Amazon on Market Negativity and Prime Day Blunders

How to Play Amazon on Market Negativity and Prime Day Blunders